GlassScriptPhysician profile
Chitharanjan Duvoor
NPI 1609131234
$75,735.26
in general payments reported to CMS, 2019-2025
62 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,368 · 2020: $2,590 · 2021: $3,500 · 2022: $4,892 · 2023: $15K · 2024: $16K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Food and Beverage: $13K · Consulting Fee: $7,525 · Travel and Lodging: $6,021 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,413 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $28,488.00 |
| Food and Beverage | $12,567.96 |
| Consulting Fee | $7,525.00 |
| Travel and Lodging | $6,020.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,412.50 |
| Education | $372.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24,662.58 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $24,227.47 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $2,275.70 | 2021-2025 | |
| Amgen INC. | $2,124.47 | 2019-2025 | Repatha, Tepezza, Repatha |
| Ge Healthcare | $1,964.97 | 2019 | |
| Novo Nordisk INC | $1,884.54 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic Minimed, INC. | $1,741.46 | 2019-2020 | |
| Lilly USA, LLC | $1,714.72 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Medtronic, INC. | $1,619.32 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Corcept Therapeutics | $1,568.81 | 2021-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $1,535.83 | 2019-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $1,060.71 | 2019-2025 | |
| Radius Health, INC. | $921.64 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $755.28 | 2019-2025 | Jardiance |
| Insulet Corporation | $703.41 | 2019-2025 | Omnipod |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $548.14 | 2024-2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $512.33 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $501.35 | 2020-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Otsuka America Pharmaceutical, INC. | $461.50 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $456.77 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $350.98 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $333.16 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $319.25 | 2020-2023 | Benlysta, Shingrix, Trelegy Ellipta |
| Sequel Med Tech, LLC | $280.69 | 2025 | Twiist |
| Fresenius USA Marketing, INC. | $269.72 | 2021-2024 | Velphoro |
| Esperion Therapeutics, INC. | $241.02 | 2020-2024 | Nexletol |
| Cequr Corporation | $236.93 | 2023-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $224.12 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Tandem Diabetes Care, INC. | $207.26 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $199.69 | 2024-2025 | |
| Daiichi Sankyo INC. | $188.67 | 2019-2023 | Injectafer |
| Travere Therapeutics, INC. | $160.71 | 2023-2024 | |
| Beta Bionics, INC. | $156.66 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Nevro Corp. | $119.08 | 2023-2024 | Senza |
| Madrigal Pharmaceuticals | $108.08 | 2024 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $107.12 | 2021-2024 | Acthar |
| Globus Medical, INC. | $98.42 | 2025 | Senza |
| Averitas Pharma INC. | $77.72 | 2023-2025 | Qutenza |
| Shire North American Group INC | $73.20 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.24 | 2022-2023 | Xifaxan |
| Horizon Therapeutics Plc | $67.75 | 2019-2022 | |
| Amarin Pharma, INC. | $57.97 | 2021 | |
| Neurocrine Biosciences, INC. | $48.22 | 2025 | |
| Ionis Pharmaceuticals, INC. | $45.92 | 2025 | Tryngolza |
| Pfizer INC. | $43.10 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $38.36 | 2020 | |
| Nuwellis, INC. | $37.95 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $34.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.58 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $33.46 | 2021 | |
| Abbvie INC. | $30.57 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.93 | 2019 | |
| Genzyme Corporation | $21.67 | 2021 | |
| Aurinia Pharma U.S., INC. | $20.00 | 2023 | Lupkynis |
| Strongbridge US INC. | $17.80 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.17 | 2022 | |
| Chiesi USA, INC. | $16.72 | 2025 | Mycapssa |
| Alvogen INC | $16.66 | 2023 | Teriparatide |
| Regeneron Healthcare Solutions, INC. | $16.65 | 2019 | |
| Becton, Dickinson and Company | $16.61 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $14.24 | 2025 | Imcivree |
| Astellas Pharma US INC | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitharanjan Duvoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.